These appointments follow the expansion of Metrion’s internal drug discovery program, driven by funding from Innovate UK, to support research into potassium ion channel inhibitors. The internal proprietary program will now be led by Dr Stevens and Dr Lightfoot, and is based on a portfolio of more than 2,000 novel small molecule inhibitors of potassium ion channels acquired by Metrion in January 2018.
Dr Edward Stevens joins Metrion from Ario Pharma, where he was chief scientific officer. Prior to this, he held various roles at Pfizer Neusentis and Pfizer Sandwich, including Head of Electrophysiology, a member of the Pain Research Unit Leadership Team, and led several ion channel discovery programs.
Dr Andrew Lightfoot is currently chief executive officer at Procarta Biosystems and in his new role at Metrion will continue in this position. He was also previously chief executive officer and founder of Peptinnovate, a UK based, clinical stage biopharmaceutical company, executive director of Swedish medtech CytaCoat AB, and chief executive officer of Helperby Therapeutics.